19
Feb

Why FDA–EMA AI Principles Matter (Part 1)

Overview of Regulatory Alignment The recent joint FDA–EMA guidance “Guiding Principles of Good AI Practice in Drug Development” has sparked conversation across the industry. Do you view it as a major shift or dismiss it as “just another guidance”? The truth usually sits between those extremes. This blog series will examine the signals, which we […]

Read More
29
Jan
spreadsheet help - Lachman Blog

Spreadsheets: Problem or Solution?

Since their introduction to the public in 1979, spreadsheets have come a long way. Even while technology has changed, from Apple II computers to artificial intelligence, spreadsheets have had incredible staying power. Nevertheless, spreadsheets struggle to keep pace with GxP requirements. In regulated companies, required to adhere to GxPs, spreadsheets can be useful, but they are […]

Read More
15
Jan
10a Watts to woes picture

From Watts to Woes: Emerging Electricity Challenges in GxP Environments

The global pharmaceutical industry is undergoing a significant transformation. Driven by supply chain resilience, regulatory incentives, and geopolitical considerations, many companies are onshoring manufacturing operations, bringing them back to domestic soil. While this shift may have a perceived promise of improved security and faster delivery of critical medicines, it also introduces the invisible risk of […]

Read More
23
Dec
FSD gage

Does Your Data Integrity Risk Assessment Assess Full-Scale Instrument Deflection? It Should!

Why Using Full-Scale Deflection Introduces Data Integrity Risks In pharmaceutical manufacturing, Accuracy is a critical ALCOA+ principle that can sometimes get lost, particularly when assessing the holistic system. The field instrument level needs to be adequately integrated into the overall assessment, especially in aseptic manufacturing environments where sterilization is critical (and accurate data, such as […]

Read More
12
Dec
Businessman chatting with chat bot on smartphone

EU AI Act Refresh: Speak Up and Problem Reporting Aspects Revised

The concepts of Speak Up and Quality Culture have received renewed attention with recent developments of the European Union’s Artificial Intelligence Act.  Lachman recently blogged about the importance of a healthy quality culture (Speak Up! Does Your Quality Culture Have a Voice?), and new proposals under the Digital Omnibus package in the EU introduce three […]

Read More
26
Nov
Rise of Bio-Incubator Spaces - Lachman Blog

The Rise of Bio-Incubator Spaces: Redefining Asset Development in Life Sciences

The life-sciences industry has long been synonymous with high barriers to entry. Traditional research and development (R&D) models demand enormous capital investment, specialized infrastructure, and a deep understanding of regulatory compliance. For startups and innovators, these requirements often translate into years of fundraising and risk before a single product reaches the market. However, the emergence […]

Read More
21
Nov
Three Global Strategies - Lachman Blog

Three Global Strategies – Will the Patient Be Better?

The effect of publicly stated economic strategies cannot be overstated. These strategies drive the direction of the global life-science ecosystem. Good companies utilize Quality Risk Management (QRM) practices to integrate them into company-specific strategies. Great companies transform them into the proverbial competitive advantage, ensuring the right drug, at the right time, to the right patient. […]

Read More
14
Nov
Four men in prison cell, one leaning against bars

Data Fraud Alert! The Economic Crime and Corporate Transparency Act 2023

This blog is another in a series providing an analysis of legislative initiatives that may impact your business.  Q4 is the time of year when many pharmaceutical companies scan the horizon and develop their enterprise risk assessments and mitigation plans, which should trigger a review of these initiatives. The Economic Crime and Corporate Transparency Act […]

Read More
11
Nov
Does Your Quality Culture Have a Voice - Lachman Blog

Speak Up! Does Your Quality Culture Have a Voice?

In the FDA-regulated industry, speaking up is a cornerstone of a mature quality culture. It refers to the reporting of deviations, risks, concerns, or unethical practices, whether related to product development, manufacturing, data integrity, or patient safety. When embedded in an organization, speaking up inherently increases detection of signals that are directly or indirectly indicators […]

Read More
03
Nov
Why DORA Should Matter to YOUR Organization - Lachman Blog

Why DORA Should Matter to YOUR Organization!

Digital resilience is a concept that often needs to be revised and redefined within an organization. The pharmaceutical industry can be slow at times to identify potential external risks and assess the potential impact to operations. Much of the work we do here at Lachman helps regulated industry anticipate and mitigate Quality Management System risks […]

Read More
1 2 3 … 6